09 April 2018
Recognised as a leading firm for Who's Who Legal: Patents and Who's Who Legal: Life Sciences 2018
www.twobirds.com/en/news/press-releases/2018/global/bird-and-bird-recognised-as-leading-firm-for-whos-who-legal

08 May 2019
Manufacturing and stockpiling waiver set to limit rights of holders of SPCs for medicines
www.twobirds.com/en/news/articles/2019/global/manufacturing-and-stockpiling-waiver-set-to-limit-rights-of-holders-of-spcs-for-medicines

On 17 April 2019, the European Parliament approved, by a large majority, an amendment of the Regulation on Supplementary Protection Certificates ("SPCs").

24 April 2020
Bird & Bird team shortlisted in multiple categories for the 8th annual LMG Life Sciences Awards 2020 Europe
www.twobirds.com/en/news/press-releases/2020/global/bird-and-bird-team-shortlisted-in-multiple-categories-for-the-8th-annual-lmg-life-sciences-awards

Our international Life Sciences & Healthcare Group is extremely proud to have been recognised among individuals and companies behind the most innovative and challenging Life Sciences work of the past year, as well as ...

07 May 2020
Getting to know our newly appointed IP Partners
www.twobirds.com/en/news/articles/2020/global/getting-to-know-our-newly-appointed-ip-partners

Our international IP team are thrilled to announce the promotion of 3 new partners today. These promotions reflect our ongoing commitment to ensure the diversity of our team develops to reflect the rich pool of talent ...

13 November 2017
Second judicial interpretation of Actavis: Court expresses different views on "normal interpretation" but follows Mylan
www.twobirds.com/en/news/articles/2017/uk/second-judicial-interpretation-of-actavis

27 October 2017
First judicial interpretation of Actavis: normal = purposive and anticipation by equivalents is out
www.twobirds.com/en/news/articles/2017/uk/first-judicial-interpretation-of-actavis

02 November 2017
Actavis, Teva and Generics t/a Mylan v ICOS and Eli Lilly: Dosage patent for tadalafil for treatment of male erectile dysfunction held invalid for obviousness on appeal
www.twobirds.com/en/news/articles/2017/uk/actavis-teva-and-generics

08 May 2018
Europe: seeking competitive research exemptions in view of the UPC Agreement - the Belgian example
www.twobirds.com/en/news/articles/2018/belgium/europe-seeking-competitive-research-exemptions-in-view-of-the-upc-agreement-the-belgian-example

In this article, we touch upon the favorable IP regime, which, provides for specific research exemptions under patent law.

30 September 2019
Bird & Bird secures win in preliminary injunction patent case before the Düsseldorf Courts
www.twobirds.com/en/news/articles/2019/germany/bird-and-bird-secures-win-in-preliminary-injunction-patent-case-before-the-dusseldorf-courts

On September 26, 2019, the Higher Regional Court of Düsseldorf confirmed on appeal that Teva Pharmaceutical Industries Ltd. (“Teva”) – one of Bird & Bird’s key clients – is entitled to a preliminary injunction against ...

04 September 2019
Patents: meaning of enablement in anticipation by prior art
www.twobirds.com/en/news/articles/2019/global/patents-meaning-of-enablement-in-anticipation-by-prior-art

The Patents Court has considered enablement in relation to anticipation of a claimed monoclonal antibody invention by prior art, and held the patent was invalid for lack of novelty; it was also obvious for lack of ...